Xbrane Biopharma (Sweden) Analysis

Xbrane Stock Analysis Notes

About 35.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 7.14. Xbrane Biopharma had not issued any dividends in recent years. Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people. For more information please call the company at 46 7 60 34 67 33 or visit https://www.xbrane.com.

Xbrane Biopharma Investment Alerts

Xbrane Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.74 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Xbrane Biopharma's market, we take the total number of its shares issued and multiply it by Xbrane Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Technical Drivers

As of the 31st of January, Xbrane Biopharma maintains the Market Risk Adjusted Performance of 0.6351, standard deviation of 4.1, and Mean Deviation of 2.61. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xbrane Biopharma AB, as well as the relationship between them.

Xbrane Biopharma Price Movement Analysis

Xbrane Biopharma Outstanding Bonds

Xbrane Biopharma Predictive Daily Indicators

Xbrane Biopharma Forecast Models

Xbrane Biopharma's time-series forecasting models are one of many Xbrane Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Xbrane Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Xbrane Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Xbrane shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Xbrane Biopharma. By using and applying Xbrane Stock analysis, traders can create a robust methodology for identifying Xbrane entry and exit points for their positions.

When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.